Identifying a Novel Endoplasmic Reticulum-Related Prognostic Model for Hepatocellular Carcinomas

Fei Ding, Jinping Li, Yong Zhang, Chengang Wang and Yonghua Yu

1Shandong University Cancer Center, Jinan, Shandong, China
2Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China
3Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Jinan, Shandong, China
4Department of Oncology, Zibo First Hospital, Zibo, China
5Department of Public Health, Zibo First Hospital, Zibo, China

Correspondence should be addressed to Yonghua Yu; sdyonghuayu@163.com

Received 25 January 2022; Revised 11 May 2022; Accepted 20 June 2022; Published 22 July 2022

Copyright © 2022 Fei Ding et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

From the standpoint of the ER (endoplasmic reticulum), we were interested in identifying hub genes that impact clinical prognosis for HCC (hepatocellular carcinoma) patients and developing an ER-related prognostic model. Using TCGA-LIHC (The Cancer Genome Atlas-Liver Hepatocellular Carcinoma) and GSE14520 datasets, we conducted a series of analyses, which included differential gene screening, clinical prognostic analysis, Lasso regression, nomogram prediction, tumour clustering, gene functional enrichment, and tumour infiltration of immune cells. Following our screening for ER-related genes (n = 1975), we conducted a Lasso regression model to obtain five hub genes, KPNA2, FMO3, SPP1, KIF2C, and LPCAT1, using TCGA-LIHC as a training set. According to risk scores, HCC samples within either the TCGA-LIHC or GSE14520 cohort were categorized into high- and low-risk groups. Compared to the high-risk group of HCC patients, patients in the low-risk group had a better prognosis of OS (overall survival) or RFS (relapse-free survival). For TCGA-LIHC training set, with the factors of risk score, stage, age, and sex, we plotted a nomogram for 1-, 3-, and 5-year survival predictions. Our model demonstrated better clinical validity in both TCGA-LIHC and GSE14520 cohorts. Additionally, events related to biological enzyme activity, biological metabolic processes, or the cell cycle were associated with the prognostic risk of ER. Furthermore, two HCC prognosis-associated tumour clusters were identified by ER hub gene-based consensus clustering. Our findings indicated a link between ER prognostic signature-related high/low risk and tumour infiltration levels of several immune cells, such as “macrophages M2/M0” and “regulatory T cells (Tregs).” Overall, we developed a novel ER-related clinical prognostic model for HCC patients.

1. Introduction

As the primary type of liver cancer, HCC has an increasing incidence and high mortality rate worldwide [1, 2]. The occurrence and progression of HCC involve the disruption of multiple organelle functions within cells, including the undesirable stimulation of the endoplasmic reticulum (ER) and mitochondria [3]. Various genes may play roles in the pathogenesis of human diseases, including cancers, by affecting the normal physiological functions of specific organelles and maintaining cellular homeostasis [4, 5]. By utilizing different machine learning approaches, a series of survival prediction models targeting specific biological events were developed [6–11]. For instance, Lasso (least absolute shrinkage and selection operator) regression was applied to build several prognostic models for HCC patients targeting ferroptosis [8], reactive oxygen species [9], amino acid metabolism [11], or the tumour microenvironment [7]. In this study, we first constructed an HCC prognostic...
model from the perspective of ER using an integrated modelling strategy (differentially expressed genes, univariate/multivariate Cox regression, and nomogram prediction). ER-associated gene expression datasets and the detailed clinico-pathological parameters of HCC patients from two publicly accessible sources, namely, TCGA-LIHC training cohort and the GSE14520 validation cohort, were fully considered during our investigation.

The endoplasmic reticulum provides a location for the synthesis of intracellular proteins, lipids, and sugars, as well as for the folding and transport of secretory proteins [12–15]. ER can be divided into two types based on the presence or absence of ribosomes attached to its outer membrane, which are known as rough and smooth endoplasmic reticulum [15, 16]. In hepatocytes, smooth endoplasmic reticulum removes lipid-soluble waste products and harmful substances of metabolism [13, 15]. ER stress signalling induced by adverse environmental stimuli, with the feature of abnormal aggregation of misfolded/unfolded proteins, was reported to be linked to modulation of cell fate or the aetiology of many clinical diseases, including cancer [13, 17, 18]. In the present study, we first utilized machine learning to build an ER-associated clinical model with high prognostic accuracy for the outcome assessment of HCC patients. Five ER-related hub genes, KPNA2 (karyopherin α2), FMO3 (flavin-containing monoxygenase 3), SPP1 (sphingosine-1-phosphate phosphohydrolase-1), KIF2C (kinesin family member 2C), and LPCAT1 (lysophosphatidylcholine acyltransferase 1), were identified. Furthermore, based on the model, we examined the potential mechanisms in terms of gene expression, Cox regression, nomogram prediction, gene functional enrichment, tumour clustering, and tumour-infiltrating status of immune cells.

2. Materials and Methods

2.1. Gene Expression Matrix and Clinical Traits. Based on the GSEA (gene set enrichment analysis) online website (http://www.gsea-msigdb.org/gsea/login.jsp), we entered “endoplasmic reticulum” in the “keywords” section, then selected the ER-related items, and finally exported the target genes ($n = 1975$). A “TCGAbiolinks” R package was used to download the gene expression matrix with the type of FPKM-UQ and clinical traits from TCGA-LIHC cohort. Meanwhile, the expression matrix, clinical traits, and annotation files of GSE14520 within the GEO (Gene Expression Omnibus) repository cohort were downloaded by using the “GEOquery” R package. Afterwards, batch correction of the expression matrix within TCGA-LIHC and GSE14520 was carried using a “sva” R package. The clinical characteristics of TCGA-LIHC and GSE14520, such as sex, age, and pathologic stage, are summarized in Supplementary Tables 1-2, respectively.
Figure 2: Continued.
Figure 2: Continued.
2.2. Differential Gene Screening. We matched clinical characteristics to the expression matrix and then screened for differential genes between normal and HCC tissues with a "limma" R package, setting log2 FC (fold change) to 1 and FDR (false discovery rate) to 0.05. Volcano and MA plots were generated using the "ggplot" R package. Additionally, heatmaps of all differential genes were created using the "pheatmap" R package.

2.3. Clinical Prognostic Analysis. After integrating TCGA-LIHC and GSE14520 data matrices with OS and RFS clinical survival status and time, a univariate Cox regression was performed using a "survival" R package with the filter of \( p = 0.05 \). The corresponding forest plots were created. Furthermore, a multivariate Cox regression analysis with forest plot visualization of the prognostic risk score, sex, age, and pathological stage was performed. Additionally, based on the prognostic signature...
Figure 3: Continued.
Figure 3: Expression pattern analysis of hub genes. We analysed the expression difference of each hub gene between HCC and normal tissues for TCGA-LIHC cohort. The (a) heatmap, (b) violin plot, and (c) expression correlation plot are shown. We also analysed the expression difference of hub genes between the HCC and paracancerous tissues. (d) The dot plots were provided, and a Wilcoxon test was conducted. (e) Histochemical results of KPNA2 and LPCAT1 proteins within the HPA database are presented. Bar, 100 μm.
Figure 4: Univariate/multivariate Cox regression analyses of risk score. Targeting the factors of prognostic risk score, sex, age, and stage, we conducted univariate/multivariate Cox regression analyses for the prognosis of OS or RFS. (a, b) TCGA-LIHC OS; (c, d) GSE14520 OS; (e, f) GSE14520 RFS.
Consensus matrix $k = 2$

Cluster 2

Cluster 1

Consensus CDF

CDF

0.0 0.2 0.4 0.6 0.8 1.0

TCGA

Relative change in area under CDF curve

Delta area

Relative change in area

Consensus index

Cluster 2

Cluster 1

TCGA

(a)

PC1

PC2

TCGA

(b)

PC1

PC2

Cluster 1

Cluster 2

FMO3

KPNA2

KIF2C

SPP1

LPCAT1

Stage

Sex

Age

S1

S2

S3

< 40

= 60

40~60

Female

Male

Figure 5: Continued.
Figure 5: Continued.
genes with a series of factors, including age, sex, pathological stage, histologic grade, Eastern Cooperative Oncology Group (ECOG), and vascular tumour cell type, the survival status was estimated using the "surv" R package, and the Kaplan–Meier survival curves were generated using "survminer" R.

2.4. Lasso Regression Model Construction. The Venn tool (http://bioinformatics.psb.ugent.be/webtools/Venn/) was used to determine the gene intersections from the univariate Cox regressions and differential expression analyses. TCGA-LIHC was adopted as a training dataset. Based on the intersecting genes, a Lasso regression model was constructed using the "glmnet" R package, and the model was visualized to determine the associated gene coefficients and risk scores. Using the gene coefficients multiplied by the expression level of each hub gene, we calculated the risk scores [8, 10, 19]. The median value of the risk score was used to differentiate high- and low-risk groups. The OS and RFS risk values for the GSE14520 validation group were then computed by the model established by TCGA-LIHC. We then plotted the survival curves for the high- and low-risk groups using the "survivor" and "survminer" R packages. Additionally, the survival status and the heatmap containing the risk score, gene expression, and related clinical features were plotted using the "pheatmap" R package. An ROC analysis of the prognostic risk score, sex, age, and stage was performed using the survivalROC R package, and an AUC (area under the ROC curve) value was calculated.

2.5. Nomogram Prediction Model. First, targeting TCGA-LIHC training set, we conducted a modelling analysis using the "regplot" R package. A nomogram was plotted. The "ggstatsplot" R package was utilized to plot the calibration curves for survival rates of 1-, 3-, and 5-year-old HCC patients. Based on the "survIDINRI" R package, the NRI (net reclassification improvement) and IDI (integrated discrimination improvement) values were calculated to explore whether the addition of risk score has an impact on the evaluation efficiency of our model. Finally, we assessed the clinical effectiveness of TCGA-LIHC-OS, GEO-OS, and GEO-RFS by means of decision curve analysis (DCA) with the "ggDCA" R package.

2.6. Correlation between Prognostic Gene Expression and Clinical Traits. We matched the expression matrix and clinical information of the ER-related genes from TCGA-LIHC dataset by using an R language approach. The expression differences of hub genes between normal and HCC tissues were analysed by a wilcox.test () R function. The "pheatmap" R package was utilized to obtain the relevant heat-maps, and the "vioplot" R package was used to draw the violin plots. The expression correlations between genes were then analysed and plotted using the "corrplot" and "psych" R packages. Based on the expression data of the target gene set between HCC and paracancerous tissues, we performed a wilcox.test for the paired samples using the "ggpubr" R package. The results were visualized by the ggdotchart () R package. In addition, the protein expression differences of these signatures between HCC and normal tissues were analysed by immunohistochemical images within the HPA (Human Protein Atlas) database.

Furthermore, we analysed the expression differences of these signatures among the different groups of clinical traits, including pathological grade, age, sex, pathological T/N/M, histologic grade, ECOG, vascular tumour cell type, adjacent hepatic tissue inflammation, and tumour status. The statistical correlations between the high/low risk and the continuous variable indices of clinical traits, including height, weight, BMI, creatinine, fetoprotein, albumin, platelets, and prothrombin time, were also analysed. The kruskal.test () R function was applied for the statistical analysis of more than two groups, and the wilcox.test () R function was applied for two groups. The data were visualized as a violin plot, box plot, bar plot, or scatter diagram by using the "ggplot2" or "ggpubr" R packages. Finally, based on the survival status and time of TCGA-LIHC-OS, GEO-OS,
Figure 6: Continued.
and GEO-RFS, we analysed the correlations between gene expression and clinical prognosis of signature genes using the R packages “survival” and “survminer.”

2.7. Tumour Cluster Analysis. Based on the expression matrix of prognostic genes, HCC patients of TCGA-LIHC and GSE14520 were clustered by a “ConsensusClusterPlus” R package [20]. Principal component analysis (PCA) was performed by a prcomp() function, and the result was visualized by the “ggplot2” R package. We matched the expression matrices of different tumour clusters and the clinical traits and then presented the results as a heatmap using the “pheatmap” R package. The “survival” R package and plot() were also utilized for cluster-specific prognostic analysis and data visualization.

2.8. Gene Enrichment Analysis. Based on the median value of the risk score, TCGA and GEO samples were divided into high- and low-risk groups, and differentially expressed genes were identified using the “limma” R package. A volcano plot was obtained by the “ggplot2” R package. The top ten differentially expressed gene-related heatmaps were generated by the “pheatmap” R package. Next, we utilized the “VennDiagram” R package for an intersection analysis of positively and negatively related gene sets from both TCGA and GEO. The gene enrichment analyses, including GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes), were then conducted by the R packages “clusterProfiler,” “org.Hs.eg.db,” and “pathview,” and the results were visualized by a barplot(). We further conducted gene set enrichment analysis (GSEA) of high/low risk using the GESA software (version 4), and the results were visualized by the R packages “plyr,” “ggplot2,” “grid,” and “gridExtra.”

2.9. Tumour-Infiltrating Immune Cell Analysis. The CIBERSORT algorithm [21] allowed us to assess the infiltration levels of immune cells in groups with high- and low-risk TCGA and calculate the percentages of 22 immune cell populations, such as “T cells CD8,” “NK cells activated,” “monocytes,” “macrophages M0/1/2,” and “dendritic cells activated.” Visualizations of the results were created with the “ggplot2” R package. Using the stat_compare_means() function, the difference between the high- and low-risk groups was analysed for the infiltration percentages of immune cells. Based on the ratios of stromal and immune cells, the “ESTIMATE” package [22] was used to determine tumour purity. The results were broken down into three columns: stromal score, immunoscore, and ESTIMATEScore. Using the “ggpubr” R package, a violin plot was created.

3. Results

3.1. Analysis Strategy. Our study is aimed at developing an ER-related prognostic model based on TCGA and GEO datasets and at exploring the potential molecular mechanisms. Figure 1 presents our analysis strategy. In brief, we first extracted the expression matrices of TCGA-LIHC and GSE14520 and performed batch correction. Targeting the ER-related genes, the corresponding ER expression matrix was extracted. Then, we conducted differential ER-related gene screening between normal and HCC tissues. In combination with clinical survival status and time, a series of univariate Cox regression analyses (including TCGA-OS, GEO-OS, and GEO-RFS) were also performed to identify prognosis-related ER genes. Based on the common genes of differential expression and univariate Cox regression analyses, we conducted a Lasso regression analysis to build a prognostic model using TCGA-LIHC as a training cohort. With the clinical
Figure 7: Continued.
Figure 7: Continued.
information, nomogram and related calibration curves at 1-, 3-, and 5-year survival times were plotted. We also calculated the values of the NRI and IRI and conducted decision curve analysis to evaluate the discrimination and clinical effectiveness of ER-related prognostic prediction signatures. We also performed a multivariate Cox regression analysis in combination with the clinical traits. Subsequent validation based on the prognostic model was carried out in a validation GSE14520 cohort, and survival curve results were obtained. In addition, we divided the HCC patients of TCGA-LIHC and GSE14520 into two groups of high/low risk and conducted differential gene analysis to obtain the intersecting genes, followed by GO, KEGG, and GSEA. Targeting the high/low risk groups, tumour-infiltrating immune cell analysis was conducted using a “CIBERSORT” approach, and tumour purity analysis was performed using the “ESTIMATE” approach. Next, the gene sets of the ER-related differential genes were obtained using TCGA-LIHC as a training set, the Lasso regression modelling analysis was then conducted to obtain five hub genes with correlation coefficients (Coef), namely, KPNA2 (0.213), FMO3 (-0.019), SPP1 (0.0348), KIF2C (0.112), and LPCAT1 (0.172). The risk scores of each sample within the TCGG-LIHC and GSE14520 cohorts were calculated by the following formula: KPNA2 expression $\times$ 0.213 $-$ FMO3 expression $\times$ 0.019 + SPP1 expression $\times$ 0.0348 + KIF2C expression $\times$ 0.112 + LPCAT1 expression $\times$ 0.172.

We classified the HCC samples into low- and high-risk groups based on the risk scores and then generated heatmaps for the gene expression profiles of the prognostic model of TCGA-LIHC and GSE14520 (Figure 2(f), Supplementary Figure 2(a)), risk profiles (Figure 2(g), Supplementary Figure 7).
Figure 8: Continued.
Figure 2(b)), survival status maps (Figure 2(h), Supplementary Figure 2(c)), survival curves (Figure 2(i), Supplementary Figure 2(d)-2(e)), and heatmaps combining clinical traits (Supplementary Figure 3-4). We observed a higher mortality rate in HCC cases with higher risk values (Figure 2(h), Supplementary Figure 2(c)). After analysing the differences in height, weight, BMI, creatinine, fetoprotein, albumin, platelets, and prothrombin time for TCGA-LIHC cases between the high- and low-risk groups (Supplementary Figure 5(a)-5(h)), we observed a slightly higher level of fetoprotein (Supplementary Figure 5(e), $p = 0.019$) but a slightly lower level of albumin (Supplementary Figure 5(f), $p = 0.041$) in the high-risk group, than in the low-risk group. HCC patients with a high-risk profile had a worse prognosis for survival than those with a low-risk profile (Figure 2(i), $p = 4.822e - 09$ for TCGA-OS; Supplementary Figure 2(d), $p = 4.331e - 03$ for GEO-OS; Supplementary Figure 2(e), $p = 4.492e - 03$ for GEO-RFS).

3.3. Expression Patterns of Hub Genes. We matched the expression matrix and the corresponding clinical traits for the expression pattern analysis for each hub gene of our
model. As shown in Figures 3(a) and 3(b), there were high expression levels of KPNA2, KIF2C, SPP1, and LPCAT1 genes \((p < 0.001)\) but a low expression level of FMO3 \((p < 0.001)\) in HCC tissues compared with normal tissues within TCGA-LIHC cohort. Further expression correlation analysis (Figure 3(c)) suggested that FMO3 showed negative correlations \((r < 0, all \ p < 0.001)\) of gene expression with KPNA2, KIF2C, SPP1, and LPCAT1. In addition, we observed positive correlations among KPNA2, KIF2C, SPP1, and LPCAT1 genes \((Figure 3(c), r > 0, all \ p < 0.001)\. Of them, there was the greatest significant difference for the correlation between KPNA2 expression and KIF2C expression \((Figure 3(c), r = 0.85, p = 5.09e−12)\. 

We also investigated the expression features of these five genes in paired HCC and paracancerous tissues from the GSE1520 cohort. As shown in Figure 3(d), there were higher expression levels of LPCAT1 \((p = 3.46e−39)\), SPP1 \((p = 1.84e−22)\), KPNA2 \((p = 1.18e−72)\), and KIF2C \((p = 2.33e−51)\) and a lower expression level of FMO3 \((p = 1.63e−29)\) in HCC tissues than in the matched paraneoplastic tissues. The immunohistochemical analysis data of the HPA database further indicated higher KPNA2 and LPCAT1 protein staining signals in HCC tissues than in normal tissues \((Figure 3(e)\. Histochemical data of LPCAT1, SPP1, and FMO3 were temporarily unavailable in the HPA database.

Next, we analysed the statistical correlations between hub gene expression and clinical traits (Supplementary Figure 6-9) within TCGA-LIHC cohort. Briefly, the expression patterns of KPNA2, FMO3, SPP1, KIF2C, and LPCAT1 were statistically correlated with the clinical stage \((Supplementary Figure 6(a), p < 0.001)\), especially the pathological T stage \((Supplementary Figure 7, p < 0.05)\. A similar result was detected for histologic grade \((Supplementary Figure 8(a), p < 0.01)\. Our findings also revealed significant correlations between KPNA2, LPCAT1, KIF2C, and SPP2 expression and three clinical traits, including ECOG \((Supplementary Figure 8(b), p < 0.01)\), vascular tumour cell type \((Supplementary Figure 9(a), p < 0.05)\), and tumour status \((Supplementary Figure 9(c), p < 0.05)\. Additionally, there were correlations between SPP1 expression and age \((Supplementary Figure 6(b), p < 0.05)\), FMO3 expression and sex \((Supplementary Figure 6(c), p < 0.001)\), and SPP1 expression and adjacent hepatic tissue inflammation \((Supplementary Figure 9(b), p < 0.05)\. For the GSE14520 cohort, we observed statistical correlations of stage with the expression levels of KPNA2, FMO3, SPP1, and LPCAT1 \((Supplementary Figure 6(d), p < 0.01)\. In addition, the age factor was correlated with the expression of KIF2C and LPCAT1 \((Supplementary Figure 6(e), p < 0.01)\. While the sex factor was linked to the expression of SPP1 \((Supplementary Figure 6(f), p < 0.01)\. 

3.4. Prognostic Analysis of Hub Genes. We also conducted prognostic analyses of TCGA-OS, GEO-OS, and GEO-RFS for each hub gene of our model. As presented in Supplementary Figure 10, HCC patients with high expression levels of KPNA2, KIF2C, SPP1, and LPCAT1 and low expression of FMO3 exhibited a poor clinical prognosis of OS and RFS. Statistically significant differences were observed in all groups \((Supplementary Figure 10(a)-10(c), p < 0.05)\. Except for KPNA2 in GSE14520 \((Supplementary Figure 10(c), p = 1.496e−01)\. When we combined the risk score and the factors of age \((Supplementary Figure 11(a)-11(b))\), sex \((Supplementary Figure 11(c)-11(d))\), pathological stage \((Supplementary Figure 12(a))\), histologic grade \((Supplementary Figure 12(b))\), ECOG \((Supplementary Figure 12(c))\), and vascular tumour cell type \((Supplementary Figure 12(d))\), we still obtained positive conclusions \((all \ p < 0.05)\. Based on the risk score of each case and the corresponding clinical traits \(sex, age, and stage)\, univariate/ multivariate Cox regression analyses were performed as well. The results in Figures 4(a)-4(f) show that both the stage and risk score were statistically correlated with the clinical prognosis of HCC patients. The higher the stage level and risk score, the worse the prognosis of OS and RFS in the HCC cases of both TCGA-LIHC and GSE14520 cohorts \(all \ HR > 1, p < 0.05)\. Subsequent ROC results indicated that the stage and risk score factors had good performance in predicting 1-, 3-, and 5-year survival rates \((Supplementary Figure 13(a)-13(c), AUC > 0.6). 

3.5. Tumour Clustering Analysis. TCGA-LIHC samples were analysed using hub genes to identify two tumour clusters \((Figure 5(a))\. Subsequently, we separated these two clusters of tumours using a PCA approach \((Figure 5(b))\. Combined with clinical characteristics, we presented heatmaps of hub gene expression for different tumour clusters and observed a significant difference between the two tumour clusters and stages \((Figure 5(c), p = 2.326e−04)\. Compared to Cluster 1, the Cluster 2 group showed high expression levels of KPNA2, KIF2C, SPP1, and LPCAT1 and a low expression level of FMO3 \((Figure 5(c))\. In addition, HCC patients in the Cluster 2 group had a poorer prognosis of OS than those in the Cluster 1 group \((Figure 5(d), p = 5.766e−06)\. We also conducted tumour clustering analysis of the GSE14520 cohort and obtained two similar tumour clusters \((Figure 5(e))\, which could also be classified by a PCA approach \((Figure 5(f))\. The two clusters were associated with the clinical stage factor \((Figure 5(g), p = 2.74e−05)\. Compared with Cluster 1, HCC patients in Cluster 2 had a worse prognosis for OS and RFS \((Figure 5(h), p = 0.02 for OS; p = 1.575e−04 for RFS). 

3.6. Nomogram and Related Assessments. First, using TCGA-LIHC training set, we developed a nomogram for predicting the 1-, 3-, and 5-year survival rates of a given case of HCC according to the combined factors of risk score, stage, age, and sex. As shown in Figure 6(a), combining the risk score, stage, age, and sex information of the selected patients, we were able to predict the survival rates for 1, 3, and 5 years, which were 0.525, 0.359, and 0.152, respectively. A high degree of overlap is evident in the calibration plot curve of Figure 6(b). The values of NRI and IDI indicated that the prediction effects of the model for 1-, 3-, and 5-year survival time improved after adding the risk score factor \((Figure 6(c), all \ IDI > 0, NRI > 0, and p < 0.05)\. Our DCA data of TCGA-LIHC \((Figure 6(d))\ and GSE14520 \((Supplementary Figures 14(a)-14(b))\ further exhibited better clinical validity in the "age + sex + stage + risk score" group than in the other groups.
3.7. Prognostic Risk-Related Differential Gene Analysis. We used the “limma” R package to identify differentially expressed genes using high/low-risk grouping in TCGA-LIHC and GSE14520 (Figures 7(a) and 7(b)). Based on an intersection analysis, 74 genes negatively associated with high risk and 56 positively associated genes were identified (Figure 7(c)). Using these differentially expressed genes, we carried out the GO and KEGG enrichment analyses (Figures 7(d) and 7(e)). These genes were associated with biological enzyme activity, biological metabolic processes, or the cell cycle, e.g., “small molecule catabolic process,” “CH-OH group of donors, NAD or NADP as acceptor,” “glycolysis/gluconeogenesis,” “carbon metabolism,” “microtubule cytoskeleton organization involved in mitosis,” “spindle,” or “mitotic spindle.” Additionally, GSEA results revealed a series of genes related to G1/S, G2/M checkpoints, and E2F targets (Figure 7(f)).

3.8. Tumour-Infiltrating Immune Cell Analysis. Finally, we utilized a “CIBERSORT” algorithm to obtain the proportions of 22 immune cell populations of each HCC patient, such as “T cells CD8,” “NK cells activated,” “monocytes,” “macrophages M0/1/2,” and “dendritic cells activated,” in the high- and low-risk groups of TCGA-LIHC cohort (Figure 8(a)). Compared with the low-risk group, the proportions of “T cells CD4 resting” and “mast cells resting” were relatively low in the high-risk group (Figure 8(b), \( p < 0.001 \)), while “plasma cells,” “regulatory T cells (Tregs),” “macrophages M0,” “macrophages M2,” and “neutrophils” were relatively high (Figure 8(b), \( p < 0.05 \)). Additionally, we utilized the “Estimate” algorithm to estimate the tumour purity. Even though we did not observe significant differences in the overall tumour purity (Figure 8(c), ESTIMATEScore, \( p = 0.66 \)) and stromal cell (\( p = 0.062 \)) ratios between the high- and low-risk groups, there was a relatively high percentage of immune cells in the high-risk group compared with the low-risk group (\( p = 0.016 \)). Collectively, these results indicated a correlation between ER prognostic model gene-related high/low risk and tumour infiltration of immune cells.

4. Discussion

Growing evidence indicates the functional links between endoplasmic reticulum-related events and the occurrence, development, and even clinical immunotherapy of cancers [23–26]. In 2021, Liu et al. published an ER stress- (ERS-) related HCC prognostic model based on TCGA-LIHC and ICGC (International Cancer Genome Consortium) datasets [27]. Five genetic variables, including HDGF, EIF2S1, SRPRB, PPP2R5B, and DDX11, were narrowed down from 88 ERS genes by means of a univariate/multivariate Cox regression approach [27]. In the current study, we focused on the ER rather than the ERS. For our ER-related prognostic model, we enrolled the different datasets from the HCC cohorts of TCGA-LIHC and GSE14520 and mainly utilized the modeling strategy approach of Lasso regression and the model effectiveness assessment methods, including ROC, calibration curves, NRI, IDI, and DCA. Finally, five prognostic gene signatures, SPPI KIF2C, LPCAT1, KPNA2, and FMO3, were identified from a total of 1975 ER-related genes, and a high assessment power was detected for the combined panel. Furthermore, we first identified two tumour clusters by consensus clustering that were closely correlated with the survival prognosis of HCC patients and provided evidence regarding the correlation between our ER-related models and a set of events, including biological enzyme activity, biological metabolic processes, cell cycle, and tumour infiltration of immune cells.

Several publications have reported the relationships between these five ER-related genes (SPP1, KIF2C, LPCAT1, KPNA2, and FMO3) and cancers. SPPI, located in the ER, is an enzyme responsible for the dephosphorylation of intracellular SIP (sphingosine-1-phosphate) [28, 29]. SPP1 is related to the upregulation of autophagy and apoptosis upon ER stress [28–30]. High expression of SPPI could promote the proliferation of HCC cells [31]. KIF2C increased the proliferation or migration ability of HCC cell lines and aggravated HCC progression, indicating a potential therapeutic biomarker for clinical HCC treatment [32–34]. LPCAT1, as an ER-resident protein, could participate in the conversion of lysophosphatidylcholine into phosphatidylcholine [35]. Highly expressed LPCAT1 was observed in several types of cancer tissues compared with normal tissues [35–37]. It was reported that LPCAT1 affected the phospholipid composition of HCC cells and modulated the progression of HCC [36, 37]. KPNA2 is involved in the nucleoplasm shuttle process of various oncoproteins, and highly expressed KPNA2 is linked to poor prognosis in patients with some kinds of cancer [38–40]. FMO3 was implicated in the modulation of cholesterol metabolism [41] and radical production in the endoplasmic reticulum [42]. It was reported that FMO3 could participate in the regulation of glucose metabolism in the liver by reducing lipid-induced ER stress [43]. Herein, we observed high expression levels of KPNA2, KIF2C, SPPI, and LPCAT1 genes but low expression levels of FMO3 in HCC tissues. The KPNA2, LPCAT1, KIF2C, and SPPI genes were statistically correlated with pathological stage, histologic grade, ECOG, vascular tumour cell type, and tumour status.

In our study, we evaluated the expression patterns and potential prognostic significance of five hub genes in HCC patients within TCGA-LIHC and GSE14520 cohorts. FMO3 presented the opposite result compared to other proteins. Briefly, HCC patients with high KPNA2, KIF2C, SPPI, and LPCAT1 expression but low FMO3 expression showed a poor survival prognosis. By combining the expression features of the five genes, we observed an improved prognostic value for OS or RFS for the 1-, 3-, and 5-year survival periods. Positive conclusions were obtained when adding the factors age, sex, and pathological stage. In addition, we obtained two clusters by consensus clustering of ER-related genes for HCC patients in TCGA-LIHC and GSE14520 cohorts. HCC patients in Cluster 2 with high KPNA2, KIF2C, SPPI, and LPCAT1 expression and low FMO3 expression showed a worse survival prognosis than HCC patients in Cluster 1.

To stratify HCC risk, a five-gene-based prognostic signature model was established by TCGA-LIHC training dataset and verified by the GSE14520 testing dataset. Good clinical prognostic competence and survival prediction accuracy were
observed for our model. Furthermore, the model-based nomogram is of potential clinical application significance to predict the survival prognosis of HCC patients. In addition, we performed a series of functional enrichments based on the differentially expressed genes between the high- and low-risk groups. Due to the links of all five hub genes for risk classification and the endoplasmic reticulum, we enriched the terms of biological enzyme activity or metabolic processes as expected. KPNA2 may have an impact on the biological behaviours of HCC by regulating DNA replication and the cell cycle [40]. We observed several enrichments in cell cycle markers, including the G1/S and G2/M checkpoints.

Growing evidence supports the point that the tumour immune microenvironment is essential for the pathological process of HCC [44–46]. A set of immune cell infiltration-associated genes reportedly showed a prognostic effect for HCC patients [33, 47]. KPNA2 expression was also positively correlated with the immune infiltration levels of B cells in HCC tissues [48]. In the present study, we investigated the microenvironmental infiltration feature for the ER model-based high/low risk groups of HCC cases through two algorithms, namely, “ESTIMATE” and “CIBERSORT.” The immune cells and stroma are the two main kinds of nontumor components within the tumour microenvironment [22]. Our finding of “ESTIMATE” indicated a relatively high infiltration proportion of immune cells in the high-risk group compared to the low-risk group. Specifically, we observed a relatively high fraction of “plasma cells” in the high-risk group compared with the low-risk group. A single-cell RNA sequencing study reported that there was a higher infiltration level of “plasma cells” in tumours of HCC with cirrhosis compared with the normal controls [49]. There was a poor survival prognosis for TCGA HCC cases with a high infiltration level of plasma cells [49]. Similarly, the HCC cases in the high-risk group exhibited a worse OS or RFS prognosis than those in the low-risk group.

Furthermore, we detected higher infiltration levels of “macrophages M2/M0” and “regulatory T cells (Tregs)” in the high-risk group than in the low-risk group. Macrophages with alternatively activated (M2) phenotypes are implicated in promoting HCC tumorigenesis [50]. In addition to “macrophages M2,” HCC patients in the cluster with enriched “macrophages M0” also exhibited a poor clinical prognosis [51]. A previous meta-analysis reported the relationship between a high infiltration status of Tregs and shorter survival time for HCC patients [52]. These findings may partly explain the poorer OS prognosis status of HCC cases in the high-risk group. Our proposed ER-related prognostic signature may be involved in the immunotherapeutic strategies of HCC.

Even though our ER-related risk model showed a high prediction performance for HCC prognosis, there were still some limitations. For instance, due to the lack of enough clinical drug treatment of HCC patients, especially for the GSE14520 cohort, we cannot adjust the effects of these clinical management factors. Our five signature-based risk model was developed by the retrospective investigation of two available sources, which still merits further validation of multicentre external datasets. Additionally, more experimental evidence is needed to confirm the potential functional links between our model and biological events, especially tumour immunity.

5. Conclusion

Taken together, we integrated the expression matrix of ER-related genes and clinical traits within both TCGA-LIHC and GSE14520 cohorts to develop and validate a novel ER-associated clinical prognostic model of HCC patients, which contains the combined panel of five hub genes (KPNA2, FMO3, SPP1, KIF2C, and LPCAT1). Additionally, we plotted a nomogram with a better clinical survival prediction performance, which may serve as a prognostic predictor to help clinicians assess the clinical survival outcomes of HCC patients.

Data Availability

The data and materials can be obtained by contacting the corresponding author.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

Fei Ding and Jinping Li contributed equally to this work.

Supplementary Materials

Supplementary 1. Supplementary Figure 1: univariate Cox regression analyses of TCGA-LIHC and GSE14520. We conducted univariate Cox regression analyses to identify a set of HCC prognosis-related candidate genes for TCGA-LIHC OS (a), GSE14520 OS (b), and RFS (c). Supplementary Figure 2: validation analysis of the Lasso regression model. Based on the risk scores of the Lasso regression model, we divided the HCC patients of GSE14520 into high- and low-risk groups. The corresponding heatmaps (a), risk profiles (b), survival status maps (c), survival curves of OS (d), and RFS (e) are shown. Supplementary Figure 3: heatmap for the hub gene expression and clinical traits of HCC patients within TCGA-LIHC cohort. Supplementary Figure 4: heatmap for the hub gene expression and clinical traits of HCC patients within the GSE14520 cohort. Supplementary Figure 5: correlations between the continuous variable index of clinical traits and high/low risk. The differences in the continuous variable index for TCGA cohorts between the high and low groups were analysed by the wilcox.test: height (a), weight (b), BMI (c), creatinine (d), fetoprotein (e), albumin (f), platelet count (g), and prothrombin time (h).

Supplementary 2. Supplementary Figure 6: correlation analysis between hub gene expression and the factors of pathological stage and age or sex. We combined the expression matrix and clinical information of five hub genes from TCGA-LIHC and GSE14520 cohorts and analysed the expression characteristics for the different pathological stages (a, d) and age (b, e), or sex (c, f), using the kruskal.test or wilcox.test. * * * p < 0.001. Supplementary Figure 7: correlation analysis between hub gene expression and pathological T/N/M. The expression differences in the five hub genes in the different pathological T/N/M groups were analysed by the kruskal.test, followed by the wilcox.test for TCGA.
cohort. (a) FMO3; (b) KIF2C; (c) KPNA2; (d) LPCAT1; (e) SPP1. Supplementary Figure 8: correlation analysis between hub gene expression and factors of histologic grade and ECOG. The expression differences of five hub genes in the different histologic grade (a) or ECOG (b) groups were analysed by the kruskal.test followed by the wilcoxon.test for TCGA cohort. Supplementary Figure 9: correlation analysis between hub gene expression and three factors. The expression differences of five hub genes in the different groups of vascular tumour cell type (a), adjacent hepatic tissue inflammation (b), and tumour status (c) were analysed by the kruskal.test and wilcoxon.test for TCGA cohort. *p < 0.05, **p < 0.01, ***p < 0.001. Supplementary Figure 10: prognostic analyses of hub genes. The survival status of LPCAT1, KPNA2, SPP1, KIF2C, and FMO3 was analysed, and the corresponding Kaplan–Meier survival curves were plotted for TCGA-LICH OS (a), GSE14520 OS (b), and GSE14520 RFS (c). Supplementary Figure 11: prognostic analysis of high/low risk combined with age and sex. The survival status of high/low risk combined with the factors of age and sex was estimated, and the corresponding Kaplan–Meier survival curves were plotted. TCGA-LICH age (a), GSE14520 age (b), TCGA-LICH sex (c), and GSE14520 sex (d). Supplementary Figure 12: prognostic analysis of high/low risk combined with the other four factors. The survival status of high/low risk combined with the factors of pathological stage (a), histologic grade (b), ECOG (c), and vascular tumour cell type (d) were estimated, and the corresponding Kaplan–Meier survival curves were plotted for TCGA-LICH. Supplementary Figure 13: ROC analysis of the risk score. Targeting the factors of prognostic risk score, sex, age, and stage, we conducted ROC analyses for the prognosis of TCGA-LICH OS (a), GSE14520 OS (b), and GSE14520 RFS (c) for the 1-, 3-, and 5-year survival times. Supplementary Figure 14: decision curve analyses for GEO14520. We conducted DCA of GSE14520 OS (a) and RFS (b) using the three groups of “age + sex,” “age + sex + stage,” and “age + sex + stage + risk score” for the 1-, 3-, and 5-year survival times, respectively. 

Supplementary 2. Table S1: clinical characteristics of HCC cases for TCGA-LIH. Table S2: clinical characteristics of HCC cases for GSE14520.

References

[1] T. Couri and A. Pillai, “Goals and targets for personalized therapy for HCC,” Hepatology International, vol. 13, no. 2, pp. 125–137, 2019.

[2] S. R. Duran and R. D. B. Jaquiss, “Hepatocellular carcinoma,” The New England Journal of Medicine, vol. 381, no. 1, article e2, 2019.

[3] M. Léveillé and J. L. Estall, “Mitochondrial dysfunction in the transition from NASH to HCC,” Metabolites, vol. 9, no. 10, p. 233, 2019.

[4] J. Zucman-Rossi, A. Villanueva, J. C. Nault, and J. M. Llovet, “Genetic landscape and biomarkers of hepatocellular carcinoma,” Gastroenterology, vol. 149, no. 5, pp. 1226–1239.e4, 2015.

[5] A. Almanza, A. Carlesso, C. Chintha et al., “Endoplasmic reticulum stress signalling – from basic mechanisms to clinical applications,” The FEBS Journal, vol. 286, no. 2, pp. 241–278, 2019.

[6] C. Huang, M. Fang, H. Feng et al., “N-glycan fingerprint predicts alpha-fetoprotein negative hepatocellular carcinoma: a large-scale multicenter study,” International Journal of Cancer, vol. 149, no. 3, pp. 717–727, 2021.

[7] S. Xiang, J. Li, J. Shen et al., “Identification of prognostic genes in the tumor microenvironment of hepatocellular carcinoma,” Frontiers in Immunology, vol. 12, article 653836, 2021.

[8] J. Y. Liang, D. S. Wang, H. C. Lin et al., “A novel ferroptosis-related gene signature for overall survival prediction in patients with hepatocellular carcinoma,” International Journal of Biological Sciences, vol. 16, no. 13, pp. 2430–2441, 2020.

[9] J. H. Xu, Y. J. Guan, Z. D. Qiu et al., “System analysis of ROS-related genes in the prognosis, immune infiltration, and drug sensitivity in hepatocellular carcinoma,” Oxidative Medicine and Cellular Longevity, vol. 2021, Article ID 6485871, 30 pages, 2021.

[10] Y. Nie, L. Liu, Q. Liu, and X. Zhu, “Identification of a metabolic-related gene signature predicting the overall survival for patients with stomach adenocarcinoma,” PeerJ, vol. 9, article e10908, 2021.

[11] Y. Zhao, J. Zhang, S. Wang, Q. Jiang, and K. Xu, “Identification and validation of a nine-gene amino acid metabolism-related risk signature in HCC,” Frontiers in Cell and Developmental Biology, vol. 9, article 731790, 2021.

[12] J. Stevenson, E. Y. Huang, and J. A. Oltmann, “Endoplasmic reticulum-associated degradation and lipid homeostasis,” Annual Review of Nutrition, vol. 36, no. 1, pp. 511–542, 2016.

[13] J. Wei and D. Fang, “Endoplasmic reticulum stress signaling and the pathogenesis of hepatocarcinoma,” International Journal of Molecular Sciences, vol. 22, no. 4, p. 1799, 2021.

[14] M. Wang and R. J. Kaufman, “Protein misfolding in the endoplasmic reticulum as a conduit to human disease,” Nature, vol. 529, no. 7586, pp. 326–335, 2016.

[15] L. B. Agellon and M. Michalak, “The endoplasmic reticulum and the cellular reticular network,” Advances in Experimental Medicine and Biology, vol. 981, pp. 61–76, 2017.

[16] D. S. Schwarz and M. D. Blower, “The endoplasmic reticulum: structure, function and response to cellular signaling,” Cellular and Molecular Life Sciences: CMLS, vol. 73, no. 1, pp. 79–94, 2016.

[17] S. J. Marciniaik, “Endoplasmic reticulum stress: a key player in human disease,” The FEBS Journal, vol. 286, no. 2, pp. 228–231, 2019.

[18] N. Siwecka, W. Rozpędek, D. Pytel et al., “Dual role of endoplasmic reticulum stress-mediated unfolded protein response signaling pathway in carcinogenesis,” International Journal of Molecular Sciences, vol. 20, no. 18, p. 4354, 2019.

[19] Y. Wu, X. Wei, H. Feng et al., “Integrated analysis to identify a redox-related prognostic signature for clear cell renal cell carcinoma,” Oxidative Medicine and Cellular Longevity, vol. 2021, Article ID 6648093, 35 pages, 2021.

[20] M. D. Wilkerson and D. N. Hayes, “ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking,” Bioinformatics, vol. 26, no. 12, pp. 1572-1573, 2010.

[21] A. M. Newman, C. B. Steen, C. L. Liu et al., “Determining cell type abundance and expression from bulk tissues with digital cytometry,” Nature Biotechnology, vol. 37, no. 7, pp. 773–782, 2019.
[22] K. Yoshihara, M. Shahmoradgoli, E. Martinez et al., "Inferring tumour purity and stromal and immune cell admixture from expression data," Nature Communications, vol. 4, no. 1, p. 2612, 2013.

[23] L. Sisinni, M. Pietrafesa, S. Lepore et al., "Endoplasmic reticulum stress and unfolded protein response in breast cancer: the balance between apoptosis and autophagy and its role in drug resistance," International Journal of Molecular Sciences, vol. 20, no. 4, p. 857, 2019.

[24] E. Mohamed, Y. Cao, and P. C. Rodriguez, "Endoplasmic reticulum stress regulates tumor growth and anti-tumor immunity: a promising opportunity for cancer immunotherapy," Cancer Immunology, Immunotherapy: CII, vol. 66, no. 8, pp. 1069–1078, 2017.

[25] H. W. Moon, H. G. Han, and Y. J. Jeon, "Protein quality control in the endoplasmic reticulum and cancer," International Journal of Molecular Sciences, vol. 19, no. 10, p. 3020, 2018.

[26] H. Kim, A. Bhattacharya, and L. Qi, "Endoplasmic reticulum quality control in cancer: friend or foe," Seminars in Cancer Biology, vol. 33, pp. 25–33, 2015.

[27] P. Liu, J. Wei, F. Mao et al., "Establishment of a prognostic model for hepatocellular carcinoma based on endoplasmic reticulum stress-related gene analysis," Frontiers in Oncology, vol. 11, article 641487, 2021.

[28] S. Lépine, J. C. Allegood, M. Park, P. Dent, S. Milstien, and S. Spiegel, "Sphingosine-1-phosphate phosphohydrolase-1 regulates ER stress-induced autophagy," Cell Death and Differentiation, vol. 18, no. 2, pp. 350–361, 2011.

[29] H. Le Stunff, I. Galve-Roperh, C. Peterson, S. Milstien, and S. Spiegel, "Sphingosine-1-phosphate phosphohydrolase in regulation of sphingolipid metabolism and apoptosis," The Journal of Cell Biology, vol. 158, no. 6, pp. 1039–1049, 2002.

[30] S. Lépine, J. C. Allegood, Y. Edmonds, S. Milstien, and S. Spiegel, "Autophagy induced by deficiency of sphingosine-1-phosphate phosphohydrolase 1 is switched to apoptosis by calpain-mediated autophagy-related gene 5 (Atg5) cleavage," The Journal of Biological Chemistry, vol. 286, no. 52, pp. 44380–44390, 2011.

[31] J. Wang, F. Hao, X. Fei, and Y. Chen, "SPP1 functions as an enhancer of cell growth in hepatocellular carcinoma targeted by miR-181c," American Journal of Translational Research, vol. 11, no. 11, pp. 6924–6937, 2019.

[32] S. Wei, M. Dai, C. Zhang et al., "KIF2C: a novel link between Wnt/β-catenin and mTORC1 signaling in the pathogenesis of hepatocellular carcinoma," Protein & Cell, vol. 12, no. 10, pp. 788–809, 2021.

[33] R. Huang, J. Liu, H. Li et al., "Identification of hub genes and their correlation with immune infiltration cells in hepatocellular carcinoma based on GEO and TCGA databases," Frontiers in Genetics, vol. 12, article 647353, 2021.

[34] G. P. Zhang, S. L. Shen, Y. Yu, X. Yue, W. J. Hu, and S. Q. Li, "Retracted: Kinesin family member 2C aggravates the progression of hepatocellular carcinoma and interacts with competing endogenous RNA," Journal of Cellular Biochemistry, vol. 121, no. 11, pp. 4419–4430, 2020.

[35] F. Mansilla, K. A. da Costa, S. Wang et al., "Sphingosine-1-phosphate acyltransferase 1 (LPCAT1) overexpression in human colorectal cancer," Journal of Molecular Medicine (Berlin, Germany), vol. 87, no. 1, pp. 85–97, 2009.

[36] Y. Morita, T. Sakaguchi, K. Ikegami et al., "Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression," Journal of Hepatology, vol. 59, no. 2, pp. 292–299, 2013.

[37] W. Jia, X. Zou, Z. Xu et al., "Polypeptide N-acetylgalactosaminyltransferase 18 retains in endoplasmic reticulum depending on its luminal regions interacting with ER resident UGGT1, PLOD3 and LPCAT1," Glycobiology, vol. 31, no. 8, pp. 947–958, 2021.

[38] Y. Han and X. Wang, "The emerging roles of KPNA2 in cancer," Life Sciences, vol. 241, article 117140, 2020.

[39] J. Li, Q. Liu, Z. Liu et al., "KPNA2 promotes metabolic reprogramming in glioblastomas by regulation of e-nyc," Journal of Experimental & Clinical Cancer Research, vol. 37, no. 1, p. 194, 2018.

[40] X. Guo, Z. Wang, J. Zhang et al., "Upregulated KPNA2 promotes hepatocellular carcinoma progression and indicates prognostic significance across human cancer types," Acta Biochimica et Biophysica Sinica, vol. 51, no. 3, pp. 285–292, 2019.

[41] M. Warrier, D. M. Shih, A. C. Burrows et al., "The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance," Cell Reports, vol. 10, no. 3, pp. 326–338, 2015.

[42] G. Catucci, C. Gao, G. Rampolla, G. Gilardi, and S. I. Sadeghi, "Uncoupled human flavin-containing monooxygenase 3 releases superoxide radical in addition to hydrogen peroxide," Free Radical Biology & Medicine, vol. 145, pp. 250–255, 2019.

[43] B. M. Liao, S. A. McManus, W. E. Hughes, and C. Schmiz-Peiffer, "Flavin-containing monooxygenase 3 reduces endoplasmic reticulum stress in lipid-treated hepatocytes," Molecular Endocrinology, vol. 30, no. 4, pp. 417–428, 2016.

[44] B. Hu, X. B. Yang, and X. T. Sang, "Development and verification of the hypoxia-related and immune-associated prognosis signature for hepatocellular carcinoma," Journal of Hepatocellular Carcinoma, vol. 7, pp. 315–330, 2020.

[45] Y. Fu, S. Liu, S. Zeng, and H. Shen, "From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma," Journal of Experimental & Clinical Cancer Research, vol. 38, no. 1, p. 396, 2019.

[46] A. J. Craig, J. von Felden, T. Garcia-Lezana, S. Sarcognato, and A. Villanueva, "Tumour evolution in hepatocellular carcinoma," Nature Reviews. Gastroenterology & Hepatology, vol. 17, no. 3, pp. 139–152, 2020.

[47] D. Wang, J. Liu, S. Liu, and W. Li, "Identification of crucial genes associated with immune cell infiltration in hepatocellular carcinoma by weighted gene co-expression network analysis," Frontiers in Genetics, vol. 11, p. 342, 2020.

[48] X. Zhang, J. Zhang, F. Gao, S. Fan, L. Dai, and J. Zhang, "KPNA2-associated immune analyses highlight the dysregulation and prognostic effects of GRB2, NRAS, and their RNA-binding proteins in hepatocellular carcinoma," Frontiers in Genetics, vol. 11, article 593273, 2020.

[49] S. Zhang, Z. Liu, D. Wu, L. Chen, and L. Xie, "Single-cell RNA-Seq analysis reveals microenvironmental infiltration of plasma cells and hepatocytic prognostic markers in HCC with cirrhosis," Frontiers in Oncology, vol. 10, article 596318, 2020.

[50] O. W. Yeung, C. M. Lo, C. C. Ling et al., "Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma," Journal of Hepatology, vol. 62, no. 3, pp. 607–616, 2015.
[51] M. Farha, N. K. Jairath, T. S. Lawrence, and I. El Naqa, "Characterization of the tumor immune microenvironment identifies M0 macrophage-enriched cluster as a poor prognostic factor in hepatocellular carcinoma," *JCO Clinical Cancer Informatics*, vol. 4, pp. 1002–1013, 2020.

[52] A. B. Zhang, Y. G. Qian, and S. S. Zheng, "Prognostic significance of regulatory T lymphocytes in patients with hepatocellular carcinoma," *Journal of Zhejiang University. Science. B*, vol. 17, no. 12, pp. 984–991, 2016.